Main Menu Pipeline and Clinical Trials Endocrine & Metabolic Compound Target Indication Phase I Phase II Phase III Relacorilant Endogenous Cushing syndrome Hypercortisolism associated with cortisol-secreting adrenal adenoma or hyperplasia Extension study to evaluate long term safety Miricorilant Antipsychotic-induced weight gain (GRATITUDE) Miricorilant Antipsychotic-induced weight gain (GRATITUDE II) Miricorilant NASH Oncology Compound Target Indication Phase I Phase II Phase III Relacorilant + Nab-paclitaxel Ovarian cancer Exicorilant + Enzalutamide Castration-resistant prostate cancer Mifepristone + Enzalutamide 1 Castration-resistant prostate cancer Mifepristone + Nab-paclitaxel2 Metastatic GR-positive triple-negative breast cancer Mifepristone + Pembrolizumab2 Metastatic HER2-negative breast cancer Relacorilant + Enzalutamide2 Castration-resistant prostate cancer Relacorilant + Pembrolizumab Adrenocortical cancer with glucocorticoid excess Neurology Compound Target Indication Phase I Phase II Phase III CORT113176 Amyotrophic lateral sclerosis (ALS) Addiction Compound Target Indication Phase I Phase II Phase III Mifepristone + Behavioral Therapy3 Alcohol use disorder Ophthalmology Compound Target Indication Phase I Phase II Phase III Mifepristone4 Central serous chorioretinopathy Psychiatry Compound Target Indication Phase I Phase II Phase III CORT1082975 Post-traumatic stress disorder (PTSD) Additional Areas of Research Alzheimer’s disease Anxiety Diabetes Hypertension Neurodegenerative diseases Nonsmall cell lung cancer Obesity GR, glucocorticoid receptor; HER2, human epidermal growth factor receptor 2; Nab-paclitaxel, nanoparticle albumin-bound paclitaxel; NASH, nonalcoholic steatohepatitis. Investigator Sponsored Trials 1University of Chicago and the National Cancer Institute. 2University of Chicago. 3Scripps Research Institute and the National Institute on Alcohol Abuse and Alcoholism. 4Bay Area Retina Associates. 5VA Office of Research and Development (estimated study start date January 1, 2021). CORCEPT'S CLINICAL TRIALS View Information on Clinical Trials CLINICAL TRIALS About Executive Team Board of Directors Educational Grants Contact Us Product Korlym for Cushing Syndrome Medical Information Request Patients Research & Pipeline Cortisol Modulation Cortisol Modulation Therapeutic Platform Pipeline and Clinical Trials Publications Investigator-Initiated Studies Compassionate Use Investors Investors Overview Press Releases Events Corporate Governance Analyst Coverage Stock Information SEC Filings Careers Benefits Testimonials Current Opportunities © 2021 Corcept Privacy Policy Terms of Use Site Map We use cookies to evaluate and improve your user experience on our website, to analyze our website traffic, and for advertising purposes. To learn more about how we use cookies, and how to change your cookie settings, please visit our Privacy Policy. By continuing to use our site you consent to our use of cookies. ACKNOWLEDGED